Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study

Published:2017-01-20 Issue:2 Volume:30 Page:196-208
ISSN:0934-0874
Container-title:Transplant International
language:en
Short-container-title:Transpl Int

Author:

O'Leary Jacqueline G.¹,Fontana Robert J.²,Brown Kimberly³,Burton James R.⁴,Firpi-Morell Roberto⁵,Muir Andrew⁶,O'Brien Christopher⁷,Rabinovitz Mordechai⁸,Reddy Rajender⁹,Ryan Robert¹⁰,Shprecher Adam¹¹,Villadiego Shirley¹¹,Prabhakar Avinash¹¹,Brown Robert S.¹²

Affiliation:

1. Department of Medicine; Baylor University Medical Center; Dallas TX USA

2. Department of Internal Medicine; University of Michigan; Ann Arbor MI USA

3. Department of Medicine; Henry Ford Hospital; Detroit MI USA

4. Department of Medicine; University of Colorado Denver; Aurora CO USA

5. Department of Medicine; University of Florida; Gainesville FL USA

6. Department of Medicine; Duke University Medical Center; Durham NC USA

7. Department of Medicine; University of Miami School of Medicine; Miami FL USA

8. Department of Medicine; University of Pittsburgh; Pittsburgh PA USA

9. Department of Medicine; University of Pennsylvania; Philadelphia PA USA

10. Janssen Research & Development; Titusville NJ USA

11. Janssen Scientific Affairs; Titusville NJ USA

12. Department of Medicine; Weill Cornell Medical Center; New York NY USA

Funder

Janssen Scientific Affairs, LLC

Gilead Sciences

AbbVie

Janssen

Hyperion

Exalenz and Duke Research

Intercept

Bristol-Myers Squibb

Merck

Conatus

Publisher

Frontiers Media SA

Subject

Transplantation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/tri.12896/fullpdf

Reference39 articles.

1. Viral hepatitis in liver transplantation;Crespo;Gastroenterology,2012

2. Hepatitis C virus reinfection after liver transplant: new chances and new challenges in the era of direct-acting antiviral agents;Herzer;World J Hepatol,2015

3. Hepatitis C recurrence after orthotopic liver transplantation: mechanisms and management;Kakati;J Clin Transl Hepatol,2014

4. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis;Wang;Am J Transplant,2006

5. Management of hepatitis C in liver transplant recipients;Kuo;Am J Transplant,2006

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of sofosbuvir‐based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta‐analysis;Journal of Clinical Pharmacy and Therapeutics;2022-06-08

2. A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation?;International Journal of Infectious Diseases;2019-06

3. The Use of Grafts from HCV+ Patients in Transplantation: Are we There Yet?;Current Hepatology Reports;2019-05-02

4. Direct‐acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta‐analysis;Transplant Infectious Disease;2019-01-21

5. Infections in Liver Transplantation;Principles and Practice of Transplant Infectious Diseases;2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3